BUYSE, Marc

Email Alert RSS Feed

Profile

Full Name
BUYSE, Marc
Email
marc.buyse@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Date Issued:  [2010 TO 2019]
Date Issued:  2016

Results 1-12 of 12 (Search time: 0.009 seconds).

Issue DateTitleContributor(s)TypeCat.
12016Data Sharing - Is the Juice Worth the Squeeze?Strom, Brian L.; BUYSE, Marc; Hughes, John; Knoppers, Bartha M.Journal ContributionA1
22016Fraud in clinical trials: complex problem, simple solutions?Sakamoto, Junichi; BUYSE, MarcJournal ContributionA2
32016Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancerMichiels, Stefan; Pugliano, L.; Marguet, S.; Grun, D.; Barinoff, J.; Cameron, D.; Cobleigh, M.; Di Leo, A.; Johnston, S.; Gasparini, G.; Kaufman, B.; Marty, M.; Nekljudova, V.; Paluch-Shimon, S.; Penault-Llorca, F.; Slamon, D.; Vogel, C.; von Minckwitz, G.; BUYSE, Marc; Piccart, M.Journal ContributionA1
42016Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group TrialTimmermans, Catherine; Doffagne, Erik; Venet, David; Desmet, Lieven; LEGRAND, Catherine; BURZYKOWSKI, Tomasz; BUYSE, MarcJournal ContributionA1
52016Statistical evaluation of surrogate endpoints with examples from cancer clinical trialsBUYSE, Marc; MOLENBERGHS, Geert; PAOLETTI, Xavier; Oba, Koji; ALONSO ABAD, Ariel; VAN DER ELST, Wim; BURZYKOWSKI, TomaszJournal ContributionA1
62016Neoadjuvant as Future for Drug Development in Breast Cancer-LetterBUYSE, Marc; BURZYKOWSKI, Tomasz; Saad, Everardo D.Journal ContributionA1
72016The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical TrialsPeron, Julien; Roy, Pascal; Ozenne, Brice; Roche, Laurent; BUYSE, MarcJournal ContributionA1
82016Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'Saad, E. D.; BUYSE, MarcJournal ContributionA1
92016Adaptive Randomization of Neratinib in Early Breast CancerBUYSE, Marc; Saad, E.; BURZYKOWSKI, TomaszJournal ContributionA1
102016An Information-Theoretic Approach for the Evaluation of Surrogate Endpoints Based on Causal InferenceALONSO ABAD, Ariel; VAN DER ELST, Wim; MOLENBERGHS, Geert; BUYSE, Marc; BURZYKOWSKI, TomaszJournal ContributionA1
112016Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsSaad, E. D.; BUYSE, MarcJournal ContributionA1
122016Neratinib after trastuzumab in patients with HER2-positive breast cancer ReplyChan, Arlene; BUYSE, Marc; Yao, BinJournal ContributionA1